SII's Covishield vaccine to be dispatched to Kathmandu, Dhaka today

With a population of nearly 30 million, the Government of Nepal plans to inoculate 72 percent of its citizens

Topics
Coronavirus Vaccine | Serum Institute of India

ANI  |  General News 

New Delhi: The first batch of Covishield vaccine reaches central storage facility at Rajiv Gandhi Super Specialty hospital in New Delhi, Tuesday, Jan. 12, 2021. (PTI Photo/ Kamal Kishore)
New Delhi: The first batch of Covishield vaccine reaches central storage facility at Rajiv Gandhi Super Specialty hospital in New Delhi, Tuesday, Jan. 12, 2021. (PTI Photo/ Kamal Kishore)

The Serum Institute of India's consignment of COVID-19 vaccines, containing 10 lakh dosages to be dispatched to Kathmandu and 20 lakh dosages to Dhaka, arrived at Mumbai's Chhatrapati Shivaji Maharaj International Airport in the wee hours of Thursday.

The flight for Kathmandu is scheduled to take off at 6:40 am while the flight for Dhaka is scheduled for 8 am.

With a population of nearly 30 million, the Government of Nepal plans to inoculate 72 percent of its citizens. Nepal has announced that legal and financial preparations for rolling out of vaccine have been completed and everything is on set with vaccination drive soon to start in the Himalayan Nation.

Apart from the latest round of vaccines to Nepal, India earlier had provided Nepal with medical equipment, medicines and other logistical support to fight the pandemic.

On January 8, Bangladesh had approved the procurement of 30 million doses of COVID-19 vaccine 'Covishield' from India.

India's Ministry of External Affairs had announced a vaccine rollout for Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles from Wednesday which comes in line with its Neighbourhood First Policy.

India had earlier supplied hydroxychloroquine, Remdesivir and paracetamol tablets, as well as diagnostic kits, ventilators, masks, gloves and other medical supplies to a large number of countries during the COVID-19 pandemic.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Thu, January 21 2021. 06:54 IST
RECOMMENDED FOR YOU